Impact of prior treatment history on efficacy of Risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials

被引：0
|
作者：
Strober, B. [1 ,2 ]
Lambert, J. [3 ]
Gu, Y. [4 ]
Zhan, T. [4 ]
Thompson, E. Z. [5 ]
Valdecantos, W. C. [4 ]
Menter, A. [6 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Farmington, CT USA
[2] Prob Med Res, Farmington, CT USA
[3] Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium
[4] AbbVie Inc, N Chicago, IL USA
[5] AbbVie Inc, Redwood City, CA USA
[6] Baylor Univ, Med Ctr, Div Dermatol, Dallas, TX USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P100
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [31] Ixekizumab impact on the skin-related relationship problems of patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2,-3)
    Warren, R. B.
    Cather, J.
    Ohtsuki, M.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 77 - 78
  • [32] Bimekizumab in patients with moderate-to-severe plaque psoriasis by bodyweight: pooled results from phase III trials
    Pinter, A.
    Strober, B.
    Rosmarin, D.
    Gisondi, P.
    Vanvoorden, V.
    Peterson, L.
    Madden, C.
    de Cuyper, D.
    Warren, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E48 - E49
  • [33] Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials
    Suleiman, Ahmed A.
    Minocha, Mukul
    Khatri, Amit
    Pang, Yinuo
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2019, 58 (10) : 1309 - 1321
  • [34] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of three randomized controlled trials
    Blauvelt, A.
    Reich, K.
    Lebwohl, M.
    Burge, D.
    Arendt, C.
    Peterson, L.
    Drew, J.
    Rolleri, R.
    Gottlieb, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E249 - E250
  • [35] High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study
    Blauvelt, A.
    Gudjonsson, J.
    Matheson, R.
    Liu, R.
    Shi, L.
    Photowala, H.
    Ehst, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (09) : B16 - B16
  • [36] Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
    Reich, Kristian
    Gooderham, Melinda
    Thaci, Diamant
    Crowley, Jeffrey J.
    Ryan, Caitriona
    Krueger, James G.
    Tsai, Tsen-Fang
    Flack, Mary
    Gu, Yihua
    Williams, David A.
    Thompson, Elizabeth H. Z.
    Paul, Carle
    LANCET, 2019, 394 (10198): : 576 - 586
  • [37] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
    Elewski, Boni
    Han, George
    Rozzo, Stephen J.
    Gogineni, Ranga
    Schenkel, Brad
    Guenthner, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
  • [38] Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
    Menter, A.
    Warren, R. B.
    Langley, R. G.
    Merola, J. F.
    Kerr, L. N.
    Dennehy, E. B.
    Shrom, D.
    Amato, D.
    Okubo, Y.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1686 - 1692
  • [39] Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
    Ohtsuki, Mamitaro
    Morita, Akimichi
    Abe, Masatoshi
    Takahashi, Hidetoshi
    Seko, Noriko
    Karpov, Alexander
    Shima, Tomohiro
    Papavassilis, Charis
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2014, 41 (12): : 1039 - 1046
  • [40] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
    Armstrong, April W.
    Lynde, Charles W.
    McBride, Sandy R.
    Stahle, Mona
    Edson-Heredia, Emily
    Zhu, Baojin
    Amato, David
    Nikai, Enkeleida
    Yang, Fan Emily
    Gordon, Kenneth B.
    JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
12345